Quarterly ResultMay 7, 2026, 09:06 AM
Theravance Biopharma Q1 Net Loss $(4.9)M; Restructuring & Ampreloxetine Wind-Down
AI Summary
Theravance Biopharma reported a net loss of $(4.9) million for the first quarter of 2026, a substantial improvement from the $(13.6) million net loss in the prior year's quarter, driven by increased revenues and reduced R&D expenses. The company also announced an organizational restructuring and the discontinuation of its ampreloxetine program after its Phase 3 clinical study did not meet its primary endpoint. Cash and cash equivalents significantly increased to $288.1 million, with strong net cash provided by operating activities.
Key Highlights
- Net loss for Q1 2026 was $(4.9) million, a significant improvement from $(13.6) million in Q1 2025.
- Total revenues increased to $17.7 million in Q1 2026 from $15.4 million in Q1 2025.
- Research and development expenses decreased to $5.8 million in Q1 2026 from $11.5 million in Q1 2025.
- Selling, general and administrative expenses were $17.7 million in Q1 2026, down from $18.4 million in Q1 2025.
- Restructuring expenses of $3.6 million were recognized in Q1 2026 due to organizational changes.
- Cash and cash equivalents stood at $288.1 million as of March 31, 2026, up from $167.8 million at December 31, 2025.
- Net cash provided by operating activities was $73.3 million in Q1 2026, compared to $43.0 million in Q1 2025.
- The ampreloxetine Phase 3 clinical study failed its primary endpoint, leading to the program's wind-down.
Price Impact
More from TBPH